Lab21 Acquires Business and Assets of Delphic Diagnostics

Lab21, (Cambridge, UK) the healthcare diagnostics company, has acquired business and assets of Delphic Diagnostics (London, UK), a specialist laboratory services business with expertise in human immunodeficiency virus (HIV) and hepatitis. The financial details of the acquisition have not been disclosed.

Delphic's business is focused on personalized medicine and companion diagnostics. It has developed a world leading expertise in pharmacology, virology, therapeutic drug monitoring, and specialist clinical trial services to the pharmaceutical industry. It has laboratories in Liverpool and in Kent and partner laboratories across Europe. It has strong quality accreditations, with more than 200 National Health Service (NHS; UK) customers and partnerships with various global pharmaceutical manufacturers.

Graham Mullis, CEO of Lab21, commented, "This acquisition is highly complementary to Lab21's existing business in companion diagnostics, and significantly extends our laboratory capacity and service offering in virology." Mr. Mullis added, "This acquisition is the latest step in our buy-and-build strategy and reinforces our market leadership position in molecular diagnostic services in the UK, specifically in the rapidly growing market for companion diagnostics."

Lab21 supplies tests and services across a broad range including pharmacogenetic tests, gold-standard viral diagnostics, cytochrome P450 genotyping, and viral resistance mapping

Related Links:
Lab21
Delphic Diagnostics